BACKGROUND: Sex differences are known to exist in the management of older patients presenting with acute myocardial infarction (AMI). Few studies have examined the incidence and risk factors of AMI among young patients, or whether clinical management differs by sex.
A
lthough there has been a dramatic decrease in mortality from coronary artery disease over the past 4 decades in the United States, this favorable trend does not appear to extend to young adults, especially younger women. 1, 2 Similarly, acute myocardial infarction (AMI) hospitalizations among young adults have not declined, 2 highlighting the need to investigate AMI in the young, a demographic group often overlooked in cardiovascular research. An increasing prevalence of obesity, cardiometabolic risk factors, and adverse health behaviors have been postulated to contribute to the observed plateau in life expectancy in the United States 3, 4 and other countries. 5 Greater burden of cardiometabolic risk factors may also lead to earlier incidence of AMI at a younger age. Previous investigations from the Atherosclerosis Risk in Communities (ARIC) study have reported a decline in AMI incidence among adults aged years from 1987 to 2008. 6 In the present investigation, we examine contemporary trends in the incidence of AMI admissions among young women and men (aged 35-54 years), who were sampled from 21 hospitals by the ARIC Surveillance study from 1995 to 2014. We also examine whether clinical management and mortality differ by sex in young patients with AMI. Although sex differences in AMI management have been well-described in older populations, 7, 8 it is uncertain whether this trend extends to younger patients presenting with AMI.
METHODS

ARIC Study Community Surveillance
The ARIC study's data and materials are publicly available. 9 As previously described 6, 10 the ARIC study has conducted community surveillance of hospitalizations for AMI in 4 geographically-defined regions of the United States (Forsyth County, North Carolina; Washington County, Maryland; Jackson, Mississippi; and 8 Northwest suburbs of Minneapolis, Minnesota). All surveillance protocols were approved by local Institutional Review Boards. Informed consent was not required, because data were anonymized by redacting personal identifiers. Community residents aged 35 to 74 years were considered eligible for surveillance in 1987 to 2004, with eligibility expanded to 35 to 84 years from 2005 to 2014. Hospitalizations were randomly sampled among strata based on race, sex, ARIC community, and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge codes: 402, 410 to 414, 427, 428 and 518. 4 . The underlying population size of residents within the 4 ARIC Communities was interpolated and extrapolated from the US Census population estimates, as previously described. 6 For the purposes of this analysis, we considered patients aged 35 to 54 years to be "young", a cutpoint consistent with prior studies 2 and representative of the lower half of the original age distribution sampled in ARIC. Importantly, hospitalizations were not sampled within any particular strata of age, provided that cases were aged 35 
Clinical Covariates and Demographic Data
Clinical and demographic data were collected from the hospital record by trained abstractors, using physician notes, laboratory reports, patient histories, and discharge summaries. Diabetes mellitus was defined by documented history of diabetes mellitus or glucose-lowering therapy use. Hypertension was defined by documented hypertension in the medical record.
Electrocardiography
The first, third, and the last 12-lead electrocardiograms (ECG) over the course of hospitalization were obtained from the medical record and coded electronically at the Minneapolis ECG Reading Center.
11
Chest Pain
Presence of chest pain was abstracted from the medical record, with origin determined by review of physician notes. Any mention of substernal pressure, tightness, or pain
Clinical Perspective
What Is New?
• In this community-based surveillance spanning 2 decades, the proportion of acute myocardial infarction hospitalizations attributable to young patients increased and was most pronounced among women.
• This trend parallels an increase in cardiovascular risk factors, including hypertension and diabetes mellitus, among young patients hospitalized with acute myocardial infarction.
• Relative to young men, young women had a higher comorbidity burden, and a lesser likelihood of undergoing an invasive strategy or being managed with guideline-based acute myocardial infarction medications.
What Are the Clinical Implications?
• An integrated, multifaceted approach is needed to promote effective primordial, primary, and secondary prevention strategies among at-risk women.
• Clinical trials designed specifically for women are required to understand further the distinct cardiovascular risk profile and to define treatment pathways in women.
• Expanding initiatives such as the American Heart Association Go Red for Women campaign to increase awareness about cardiovascular disease risk in women through media and other outlets should also be encouraged. ORIGINAL RESEARCH ARTICLE precipitated by exertion or excitement was considered evidence of chest pain of cardiac origin. Chest pain specified in the physician notes as "unknown origin" or "undiagnosed" was considered "unknown."
AMI Classification
As previously described, 10, 11 events were classified by the ARIC study as definite, probable, suspected, or no MI, based on ECG evidence (evolving diagnostic, diagnostic, evolving ST-segment/T-wave changes, equivocal, or absent/uncodable), presence of chest pain, and cardiac biomarkers (which were considered "abnormal" if ≥2x the upper limit of normal (ULN), and "equivocal" if exceeding the ULN but <2x the ULN). 6 Classification criteria remained constant over the study period and are detailed in the ARIC Study surveillance manual. 12 Classification of an event as definite or probable AMI required the presence of at least 1 of the following: (1) evolving diagnostic ECG pattern; (2) diagnostic ECG pattern and abnormal biomarkers; (3) cardiac pain and abnormal biomarkers; (4) cardiac pain and equivocal biomarkers with evolving ST-segment/ T-wave pattern or diagnostic ECG pattern; or (5) abnormal biomarkers with evolving ST-segment/T-wave pattern.
Biomarkers
Laboratory values for biomarkers of cardiac injury were recorded for the first 4 days of hospitalization. The laboratoryspecified ULN was recorded, and biomarker values were abstracted chronologically, recording up to 3 measurements per day.
Medical Therapies
Medications were recorded if administered during hospitalization or prescribed at hospital discharge. Aspirin required routine rather than pro re nata administration for abstraction. Nonaspirin antiplatelet therapy was recorded as a single category and included P2Y 12 inhibitors (cangrelor, clopidogrel, prasugrel, ticagrelor, ticlopidine), glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban), phosphodiesterase 3 inhibitors (cilostazol), phosphodiesterase 5 inhibitors (dipyridamole), and protease-activated receptor-1 antagonists (vorapaxar). Beta blockers included β 1 adrenergic antagonists. Angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers (ACEi/ARB) were recorded as a single category. Lipidlowering agents included statins, niacin, and fibrates.
Procedures
Echocardiography, stress testing, angiography and revascularization procedures were abstracted from the medical record. Echocardiography included transthoracic and transesophageal echocardiograms. Stress testing included exercise testing (treadmill or bicycle ergometer), stress echocardiography, cardiac stress MRI, and nuclear stress tests. Revascularization included percutaneous coronary intervention or coronary artery bypass graft surgery.
Mortality Outcomes
In-hospital, 28-day, and 1-year mortality were ascertained by the ARIC Study, which linked hospitalizations with the National Death Index. Cardiovascular death was defined by death due to "diseases of the circulatory system" (ICD-9 codes 390-459 and ICD-10 codes I00-I99).
Statistical Analysis
All statistical analyses were carried out using SAS 9.4 (SAS Institute; Cary, NC). Statistical tests and models accounted for the stratified sampling design and were weighted by the inverse of the sampling probability. 13 Continuous variables were assessed for normality and compared using the difference in least square means from weighted linear regression. Categorical variables were compared using Rao-Scott χ 2 tests. The annual incidence of AMI hospitalizations among young patients was calculated by dividing the weighted number of sampled AMI hospitalizations by the total number of ARIC residents aged 35 to 54 years. Although the ARIC study expanded the sampling to include patients aged 75 to 84 from 2005 to 2014, we analyzed the percentage of young community residents relative to the total population of 35-to 74-year-old residents of the ARIC communities. Similarly, the proportion of AMI hospitalizations attributable to young patients was examined among 35-to 74-year-old patients admitted with AMI across all years of observation. Trends over time were visually plotted and analyzed across 5-year intervals (1995-1999, 2000-2004, 2005-2009 , 2010-2014) using logistic regression, with year categories regressed as an ordinal variable. Trends in the prevalence of cardiovascular risk factors were limited to comorbidities routinely abstracted across all study periods.
Among young patients, the relative probabilities of women versus men receiving guideline-directed AMI medications (aspirin, other antiplatelets, beta blockers, and lipid-lowering medications) or undergoing invasive procedures (angiography and revascularization) were compared in 5-year intervals and in the aggregate. Associations were derived from multivariable logistic regression, with odds ratios converted into relative risks (RR) and 95% confidence intervals (CI).
14 Models were adjusted for race, geographic region, and year of admission. As sensitivity analyses, we also stratified the models by race, limited the population to patients with first-occurring AMI, and additionally adjusted for comorbidities and complications (diabetes mellitus, acute heart failure/pulmonary edema, ventricular fibrillation, cardiac arrest, and cardiogenic shock). One-year all-cause mortality was compared between young women and men using multivariable Cox regression, adjusted for race, geographic location, and year of admission.
RESULTS
The annual incidence of AMI hospitalizations decreased from 1995 to 2014 among male ARIC community residents aged 35 to 54. In contrast, a declining incidence of AMI hospitalizations was not observed for women aged 35 to 54 ( Figure 1A) . Evidence of population aging was noted for both sexes, with the percentage of ARIC community residents aged 35 to 54 declining over time relative to the entire population of 35 to 74-yearold residents ( Figure 1B) . However, the annual proportion of AMI admissions attributable to young patients steadily
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increased over time, with the largest increase observed in women ( Figure 1C ). When analyzed across 5-year intervals (1995-1999, 2000-2004, 2005-2009, and 2010-2014) , the proportion of AMI admissions attributable to young patients significantly increased, from 27% to 32%; P for trend<0.0001 (21% to 31% among women [P for trend <0.0001] and 30% to 33% among men [P for trend = 0.1]. Stratified trends among black women, white women, black men, and white men are shown in Table 1 . From 1995 to 2014, medical records from 28 732 weighted AMI hospitalizations (15 081 unweighted) were abstracted from sampled patients aged 35 to 74. Of these, 8737 (30%) were young, constituting our study population (Table 2) . Compared with young men, young women were more often black (52% versus 41%), and more likely to have medical insurance (85% versus 78%), history of hypertension (71% versus 64%), diabetes mellitus (39% versus 26%), chronic kidney disease (24% versus 19%), and prior stroke (10% versus 6%), when aggregated across 1995 to 2014. However, young women were less likely to be smokers (48% versus 57%). During the hospital visit, acute pulmonary edema/heart failure was more frequent among women (28% versus 22%). On the other hand, young women were less likely to have ST-segment elevation myocardial infarction (STEMI) compared with their male counterparts (16% versus 26%).
Among young women and men admitted with AMI, the annual prevalence of smoking steadily decreased, while the prevalence of hypertension and diabetes increased ( Figure 2 ). History of previous AMI remained stable over time. When examined across 5-year intervals, the overall prevalence of hypertension significantly increased (59% to 73%, P for trend<0.0001) as did prevalence of diabetes mellitus (25% to 35%, P for trend<0.0001). On the other hand, prevalence of smoking significantly decreased (60% to 52%, P for trend=0.0002) and history of prior AMI remained comparable (32% to 27%, P for trend=0.1), Table 3 .
Compared with young men, at the time of hospitalization, young women were less likely to be administered lipid-lowering medications (63% versus 72%; P<0.0001), nonaspirin antiplatelet therapy (51% versus 62%; P<0.0001), beta blockers (81% versus 84%; P=0.04), or ACEi/ARBs (59% versus 64%; P=0.02); and less often underwent invasive coronary angiography (59% versus 66%; P=0.0009) or revascularization (38% versus 50%; P<0.0001). However, women were more likely to be imaged by echocardiography (58% versus 53%; P=0.008). Aspirin administration (86% versus 89%; P=0.09); and noninvasive stress testing (7% versus 8%; P=0.6) did not differ by sex. Annual trends in the administration of therapies for young women and men presenting with AMI are shown in Figure 3 .
When aggregated across 1995 to 2014 and adjusted for race, ARIC center, and year of admission, women had a 13% lower probability of receiving lipidlowering agents (RR=0.87; 95% CI, 0.80-0.94), 17% lower probability of receiving nonaspirin antiplatelets (RR=0.83; 95% CI, 0.75-0.91), 7% lower probability of receiving angiography (RR=0.93; 95% CI, 0.86-0.99), and 21% lower probability of receiving revascularization (RR=0.79; 95% CI, 0.71-0.87). The adjusted probabilities of aspirin administration (RR=0.98; 95% CI, 0.94-1.01) and receipt of beta blockers (RR=0.96; 95% CI, 0.91-0.99) were comparable. As shown in Figure 4 , lower utilization of nonaspirin antiplatelets and lipid-lowering agents persisted for women relative to men, irrespective of non-ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction classification. However, the overall sample of patients classified with ST-segment elevation myocardial infarction was small (n=1788). Adjusted probabili- When grouped into 5-year intervals, emerging sex differences were observed for receipt of lipid-lowering agents and coronary revascularization (Table 4) ; probabilities of receiving other guideline-directed therapies changed little over time between the 2 sexes.
Among these young AMI patients, the overall allcause mortality was modest and similar between women and men (1% versus 2% for in-hospital, 4% each for 28-day, and 9% versus 7% for 1-year). Annual trends in all-cause mortality are shown in Figure I in the online-only Data Supplement. Cardiovascular mortality was also similar between women and men (1% each for in-hospital, 2% each for 28-day), but marginally higher for women by 1 year of follow up (5% versus 3%; P=0.08). After adjustment for race, hospital geographic location, and year of admission, the hazard of 1-year all-cause mortality was comparable for women versus men (HR=1.10; 95% CI, 0.83-1.45).
DISCUSSION
In this community-based surveillance of patients hospitalized with AMI, we observed a significant increase in patients presenting with AMI who were <55 years of age from 1995 to 2014. This trend parallels an increase in cardiovascular risk factors, including hypertension and diabetes mellitus, in this population. However, the increasing proportion of AMI attributable to young patients was most pronounced among women. Relative to young men, young women had a higher comorbidity burden, and a lesser likelihood of undergoing an invasive strategy or being managed with guideline-based AMI medications.
Previous studies in the US have investigated hospitalizations among young patients using administrative claims records. 2 In contrast, the ARIC Surveillance study classifies AMI by standardized physician review of the medical record, providing a more comprehensive event classification and allowing an analysis of trends spanning several decades. The increase in AMI hospitaliza- ‡Classifications of ST-segment elevated myocardial infarction vs. non-ST-segment elevation myocardial infarction available in a subset of patients (n=7844) with sufficient electrocardiographic data.
ORIGINAL RESEARCH ARTICLE
tions attributable to young patients is staggering in the background of the aging general US population. 15 Ideally, prevention of atherosclerotic cardiovascular disease should begin early in adolescence and young adulthood; however, few tools exist to assess the risk of coronary disease in these age groups. 16 This likely results in decreased recognition of risk factors in young adults and suboptimal utilization of preventive strategies. An analysis from the Partners YOUNG-MI registry reported a low proportion (12.5%) of young adult patients on statins at the time of AMI; the authors advocate for improved risk assessment tools in this age group. 17 Sim- ORIGINAL RESEARCH ARTICLE ilarly, in the VIRGO study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) study, only half of young AMI patients believed they were at risk for heart disease prior their event, despite a high overall prevalence of cardiac risk factors. 18, 19 While the proportion of young AMI hospitalizations remained fairly stable across 1995 to 2014 among men, AMI hospitalizations attributable to young patients steadily increased among women, becoming comparable to that of young men in more recent years. Our observations complement Canadian registries reporting an increase in AMI hospitalizations among women. 20 The reasons for the rise in AMI hospitalizations among young women is likely multifactorial but may be related to modifiable risk factors. In the ARIC Community Surveillance study, young women presenting with AMI had more comorbidities and traditional risk factors than their male counterparts with AMI. This may be reflective of trends in the general nonhospitalized population. In an analysis from the National Health and Nutritional Examination Survey comparing 1988 to 1994 and 1999 to 2004, the mean Framingham coronary risk score improved for men while it worsened for women, narrowing the gap in cardiovascular risk between sexes. 21 We also noted that young women were more likely to be insured, which may have influenced care-seeking behavior and AMI hospitalizations. 22 Clinical improvement in AMI management is an important priority for the Centers for Medicare and Medicaid Services Inpatient Quality Reporting program. 23 Quality improvement initiatives have led to better outcomes for patients with AMI, irrespective of sex. 23 In this analysis from the ARIC Community Surveillance, young women presenting with AMI had a higher co- 
morbidity burden and were less likely to undergo angiography or be managed by guideline-based AMI medications. These observations are consistent with the VIRGO study, which reported greater prevalence of diabetes mellitus, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and morbid obesity among women compared with men. 18, 19 An association between higher comorbidity burden and lower likelihood of angiography or evidence-based care has been reported in older patients presenting with AMI. 24, 25 Whether these associations extend to young adults with a lower likelihood of frailty is uncertain. It is possible that a greater proportion of women presented with type 2 myocardial infarction, given their greater comorbidity burden and decreased rates of revascularization. Although sex differences in management of AMI based are well known in older adults, 7, 8 few studies to date have demonstrated sex-specific differences in management of AMI among young patients.
26,27
Although the Centers for Medicare and Medicaid Services Inpatient Quality Improvement Program has focused on improving management and outcomes of patients with AMI, few initiatives have focused on improving cardiometabolic risk profiles, particularly for women. 1 Traditionally misconceived as a "man's disease", recognition of cardiovascular risk in female patients is lower than for male patients with similar risk profiles. 28 However, atherosclerotic cardiovascular disease is the leading cause of death in women. 1 Moreover, there are several nontraditional cardiac risk factors unique to women, such as gestational diabetes mellitus, preeclampsia, eclampsia, and early menopause or menarche. 29, 30 Social determinants of health such as psychosocial stressors and poverty, both with higher prevalence in women, are also associated with increased cardiovascular risk. 28, 31 We believe an integrated, multifaceted approach is needed to promote effective primordial, primary, and secondary prevention strategies among at-risk women. To understand further the distinct cardiovascular risk profile and to define treatment pathways in women, clinical trials could be designed specifically for women. Guidelines focused on preventing cardiovascular diseases in women should continue to be updated and implemented in practice, to assist clinicians in clinical decision-making. 32 Expanding initiatives such as the American Heart Association Go Red for Women campaign to increase awareness about cardiovascular disease risk in women through media and other outlets should also be encouraged.
Our study has some limitations. The ARIC Community Surveillance Study is localized to 4 US communities and may not be generalizable to the entire nation. Clinical data were limited by availability in the medical record and abstraction priority. Temporal changes in diagnostic testing and documentation may have influenced trends in risk factors over time. We were un- 33, 34 Substance use, such as cocaine and marijuana, was not abstracted from the medical record but is a known risk factor that is prevalent among young patients presenting with AMI. 35 Mortality in this young population was modest, limiting the statistical power of comparisons between women and men. Other clinically-relevant endpoints, such as hospital readmissions or major adverse cardiovascular events, may prove to differ by sex for young patients with AMI; however, these outcomes were not available for analysis. Finally, specific troponin assays and their associated sensitivities varied across hospital systems and over time, potentially influencing trends in AMI detection. Our study also has several noteworthy strengths. The ARIC Study provides a large, multi-year surveillance of 4 diverse US communities, allowing an analysis of contemporary trends spanning several decades. Clinical and laboratory values were meticulously collected by certified abstractors following standardized protocols. AMI was classified and adjudicated by physician review of the medical records, and mortality outcomes verified by the National Death Index.
CONCLUSIONS
Young patients presenting with AMI are becoming increasingly common, have high prevalence of cardiometabolic comorbidities, and face 1-year mortality rates that approach 10%. Relative to young men, young women presenting with AMI have a higher comorbidity burden and a lower likelihood of undergoing an invasive strategy or receiving guideline-based AMI therapies. These observations from the ARIC Community Surveillance study have important health implications considering the increased disability-adjusted life years associated with AMI at a younger age. There is an enduring need for effective preventive strategies to reduce the burden of cardiovascular disease in the young population, especially among young women. Ongoing primordial, primary, and secondary prevention efforts are urgently needed to promote uniform and guideline-based care targeting AMI, associated cardiometabolic comorbidities, and adverse health behaviors in the young population.
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